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BACKGROUND: Aromatase inhibitor (AI) therapy results in substantial survival benefits for patients with hormone receptor-positive
breast cancer. The rates of poor adherence and discontinuation of AI therapy are high, primarily because of treatment-related toxic-
ities like musculoskeletal pain. Although pain-related symptoms may worsen during AI therapy, the authors hypothesized that non-
persistence with AI therapy was associated with symptoms that were present before treatment initiation. METHODS:
Postmenopausal women initiating AI therapy who were enrolled in a prospective clinical trial completed questionnaires at baseline to
assess sleep, fatigue, mood, and pain. Reasons for treatment discontinuation during the first year of treatment were recorded. Associ-
ations between baseline patient-reported symptoms and treatment discontinuation because of toxicity were identified using logistic
regression. RESULTS: Four hundred forty-nine patients were evaluable. The odds of treatment discontinuation were higher in patients
who reported a greater number of symptoms before AI initiation. Baseline poor sleep quality was associated with early treatment dis-
continuation, with an odds ratio (OR) of 1.91 (95% confidence interval [CI], 1.26-2.89; P5.002). Baseline presence of tired feeling and
forgetfulness had similar ORs for discontinuation (tired feeling: OR, 1.76; 95% CI, 1.15-2.67; P5.009; forgetfulness: OR, 1.66; 95% CI, 1.11-
2.48; P5.015). An increasing total number of baseline symptoms was associated with an increased likelihood of treatment discontinu-
ation, with an OR of 1.89 (95% CI, 1.20-2.96; P5.006) for 3 to 5 symptoms versus 0 to 2 symptoms. CONCLUSIONS: Symptom clus-
ters in breast cancer survivors that are present before the initiation of adjuvant AI therapy may have a negative impact on a patient’s
persistence with therapy. Interventions to manage these symptoms may improve breast cancer outcomes and quality of life. Cancer
2014;120:2403-11. VC 2014 American Cancer Society.
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INTRODUCTION
Aromatase inhibitors (AIs) are routinely used for adjuvant therapy of postmenopausal women with estrogen receptor
(ER)-positive, early stage breast cancer. Randomized controlled trials have demonstrated improvements in disease-free
survival (DFS) and overall survival (OS) with AI therapy compared with tamoxifen.1,2 Early discontinuation of AI ther-
apy, however, has been observed in>25% of patients, primarily caused by the toxicity of therapy.3,4 Nonadherence to AI
therapy has been associated with increases in mortality.5
The most common toxicities reported by AI-treated patients are musculoskeletal symptoms, including arthralgias
and myalgias.3 Attempts to identify the cause of these side effects have focused on clinical and treatment factors, such as
time since menopause, body mass index (BMI), prior tamoxifen therapy, and prior taxane chemotherapy.3,6-8 Despite
those studies, the etiology of AI toxicity remains undefined, although it is believed to be caused, at least in part, by estrogen
depletion.9,10 Vitamin D deficiency may also play a role in the development of toxicity.11
Studies of breast cancer survivors have demonstrated high rates of patient-reported symptoms, including pain,
insomnia, fatigue, cognitive dysfunction, and mood disorders, which can be present during all phases of treatment and
can persist into the survivorship period.12,13 A similar constellation of symptoms is commonly reported by patients with
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other chronic pain conditions, including fibromyalgia
and temporomandibular joint disorder.14 In patients with
breast cancer, these symptoms may partly arise from the
multiple treatment modalities used for disease manage-
ment, including surgery, chemotherapy, radiation ther-
apy, and=or endocrine therapy. In addition, these
symptoms may be related to the stress of the diagnosis
itself.15
By using data from the 503-patient Exemestane and
Letrozole Pharmacogenetics (ELPh) trial, we previously
reported associations between clinical and treatment fac-
tors and early discontinuation of therapy because of toxic-
ity.3 In that study, >75% of patients reported
musculoskeletal pain at the time of discontinuation. On
the basis of the literature from other chronic pain disor-
ders, we hypothesized that some breast cancer patients
who develop musculoskeletal pain might also have other
symptoms that are observed in response to stressors, such
as sleep disturbances, fatigue, mood disorders, and cogni-
tive dysfunction.16 If this were the case, then it is possible
that some individuals would discontinue AI therapy
because of their total symptom burden at baseline, not
solely because of the emergence of their musculoskeletal
pain.17,18 In this article, we report associations between
the presence of patient-reported symptoms before the ini-
tiation of an AI and treatment discontinuation within 1
year of starting the drug in the ELPh trial.
MATERIALS AND METHODS
Study Participants
Postmenopausal women with stage 0 through III hor-
mone receptor-positive breast cancer who were initiating
treatment with an AI were eligible for enrollment on the
ELPh trial (clinicaltrials.gov identifier NCT00228956).
Details of the ELPh trial have been reported elsewhere.19
In brief, all indicated surgery, chemotherapy, and radia-
tion therapy were completed before enrollment, and
patients who previously received tamoxifen therapy were
permitted to enroll. The clinical trial was approved by the
institutional review boards at all 3 participating sites, and
patients were required to provide written informed con-
sent before undergoing study-related procedures.
Study Procedures
Patients were randomized 1:1 to treatment with oral
exemestane (Aromasin; Pfizer, New York, NY) 25 mg
daily or oral letrozole (Femara; Novartis, Basel, Switzer-
land) 2.5 mg daily. Before AI initiation, enrolled patients
completed a battery of questionnaires and underwent
phlebotomy. Patients then initiated treatment and
returned to the clinic for follow-up assessments, including
phlebotomy and questionnaire completion, after 1
month, 3 months, 6 months, 12 months, and 24 months
of AI therapy.
Questionnaires
At each time point, patients completed the following ques-
tionnaires: depression (Center for Epidemiologic Studies-–
Depression [CESD])20; anxiety (Hospital Anxiety and
Depression Scale-Anxiety [HADS-A])21; sleep quality
(Pittsburgh Sleep Quality Index [PSQI])22; and general
symptoms, including joint pain, fatigue, difficulty concen-
trating, forgetfulness, and vaginal dryness (the Breast Can-
cer Prevention Trial [BCPT] SymptomChecklist).23
Laboratory Studies
Serum samples obtained at the baseline and 3-month time
points were assayed for estradiol (E2), estrone-1-sulfate
(E1S), and estrone (E1) using an ultrasensitive gas
chromatography tandem mass spectroscopy assay, as
previously described.24 The lower limits of quantification
were 0.625 pg=mL for E2, 2.88 pg=mL for E1S, and
1.56 pg=mL for E1.
Statistical Plan
The primary objective of the ELPh trial was to determine
the genetic predictors of change in breast density after 24
months of either an azole (letrozole) or a steroidal
(exemestane) AI medication; those results are being pub-
lished separately.25 The primary objective of the explora-
tory analysis reported in this article was to investigate
associations between patient-reported symptoms before
AI initiation and discontinuation of AI therapy because of
toxicity during the initial 12 months of therapy.
Validated questionnaires to evaluate fatigue or cog-
nitive dysfunction were not included in this trial. There-
fore, to investigate these symptoms, the following
individual items on the BCPT questionnaire23 were ana-
lyzed: “joint pain” (pain), “forgetfulness” and “difficulty
concentrating” (cognitive dysfunction), and “tired feel-
ing” (fatigue). “Vaginal dryness” was also analyzed as a
common AI-related symptom, which is believed to be pre-
dominantly peripherally mediated rather than centrally
mediated. The presence of each symptom was defined as
the patient reporting any degree of severity of the symp-
tom (ie, slightly, moderately, quite a bit, or extremely).
Descriptive analyses were conducted of all baseline
characteristics for the entire sample and by discontinua-
tion status. Odds ratios (ORs) and their significance com-
paring the characteristics of women who discontinued AI
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therapy because of symptoms by the end of 1 year with
the characteristics of women who remained on treatment
at 1 year were calculated using logistic regression. Baseline
characteristics that were associated with AI discontinua-
tion because of symptoms by the end of the first year by a
P value < .20 were included in a multivariable model in
which a stepwise procedure was used to identify those var-
iables that were associated significantly with AI discontin-
uation because of toxicity. Estrogen measurements were
natural log-transformed in all models.
In addition, symptoms were combined to account for
the total number of symptoms each patient experienced at
baseline. Symptoms that were included in this variable
were sleep quality (poor [PSQI >5] vs good [PSQI 5]),
concentration (any severity vs none or no severity), tired
feeling (any severity vs none or no severity), anxiety (none
or no: HADS-A 7 vs borderline or definite: HADS-A
>7), and depression (none [CESD <16] vs possible or
probable [CESD 16]). If the baseline characteristic score
was missing, then it was conservatively coded as a 0, and
the total number of symptoms was summed for each
patient for a final number of symptoms ranging from 0 to
5. The total number of symptoms was dichotomized as ei-
ther from 0 to 2 or from 3 to 5, and the association between
this variable and AI discontinuation was assessed in the uni-
variate and multivariable setting. All analyses were per-
formed in SAS version 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
Baseline Patient Characteristics and Treatment
Discontinuation Caused by Toxicity
The ELPh trial included 503 patients, of whom 500 were
randomly assigned to letrozole or exemestane for 24
months (Fig. 1). Enrolled patients who discontinued ther-
apy within 1 year of treatment initiation because of toxic-
ity were compared with those who continued study
participation beyond the 1-year time point (Table 1).
During the 24-month study, in total, 51 patients discon-
tinued therapy for reasons other than treatment-emergent
toxicity, including inability to undergo phlebotomy and
recovery of ovarian function, as previously reported.3
Of the 449 patients who were eligible for the analy-
sis, 140 (31.2%) discontinued AI therapy because of
symptoms by the end of the first year of treatment (Table
1). Patients who discontinued therapy were significantly
younger than those who continued therapy (median age,
56 years vs 60 years; OR, 0.97; 95% confidence interval
[CI], 0.95-1.00; P5 .035). As previously reported,3 no
univariate statistically significant association (at the
P5 .05 level) was identified between treatment discontin-
uation and BMI (P5 .76), baseline serum estrogen con-
centration (E2, P5 .50; E1S, P5 .18; and E1, P5 .73),
race (P5 .33), previous receipt of chemotherapy
(P5 .51), taxane-based chemotherapy (P5 .18), radia-
tion therapy (P5 .51), prior tamoxifen (P5 .18), or prior
hormone-replacement therapy (P5 .18). Similarly, there
was no statistically significant association between stage of
breast cancer at diagnosis and the likelihood of treatment
discontinuation (P5 .99). Treatment with exemestane
was associated significantly with an increased risk of treat-
ment discontinuation compared with letrozole treatment
(OR, 1.67; 95%CI, 1.12-2.51; P5 .012).
Although half of the analyzed patients started AI
therapy within 6 months of undergoing definitive surgery,
the time interval ranged from 0 to 109 months. The time
from surgery to the initiation of AI therapy was not
Figure 1. This is a Consolidated Standards of Reporting Trials (CONSORT) diagram of patient flow in the Exemestane and Letro-
zole Pharmacogenetics trial (d=c indicates discontinued).
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TABLE 1. Baseline Patient Characteristics by Aromatase Inhibitor Treatment Discontinuation Statusa
Total, n 5 449
Discontinued
Because of
Symptoms,
n 5 140
All Others,
n 5 309
Characteristic No. %b No. %b No. %b OR [95% CI] P
Age (median value) 449 (59) 140 (56) 309 (60) 0.97 [0.95-1.00] .035
BMI, kg/m2b 448 (29.1) 140 (28.7) 308 (29.3) 1.00 [0.96-1.03] .76
Estradiol, pg/mLc 436 (4.7) 132 (4.1) 304 (4.9) 0.91 [0.71-1.18] .50
Estrone sulfate, pg/mLc 432 (243.5) 128 (275) 304 (228) 1.20 [0.92-1.56] .18
Estrone, pg/mLc 437 (23) 133 (21.7) 304 (23.8) 0.95 [0.68-1.31] .73
Race
White 401 89.3 128 91.4 273 88.3 1.00 [—] .33
Black/other 48 10.7 12 8.6 36 11.7 0.71 [0.36-1.41]
Breast cancer stage
DCIS 27 6 8 5.8 19 6.2 1.00 [—] .99
I 234 52.3 73 52.5 161 52.3 1.08 [0.45-2.57]
II 143 32 45 32.4 98 31.8 1.09 [0.44-2.68]
III 43 9.6 13 9.4 30 9.7 1.03 [0.36-2.95]
Chemotherapy
Yes 200 44.5 64 45.7 136 44 1.07 [0.72-1.60] .51
No 249 55.5 76 54.3 173 56 1.00 [—]
Taxane
Yes 144 32.1 51 36.4 93 30.1 1.33 [0.87-2.03] .18
No 305 67.9 89 63.6 216 69.9 1.00 [—]
Radiation therapy
Yes 355 79.4 113 81.3 242 78.6 1.19 [0.72-1.97] .51
No 92 20.6 26 18.7 66 21.4 1.00 [—]
Tamoxifen
Yes 163 36.5 57 41 106 34.4 1.33 [0.88-2.00] .18
No 284 63.5 82 59 202 65.6 1.00 [—]
Hormone-replacement therapy
Yes 231 51.8 65 47.1 166 53.9 0.76 [0.51-1.14] .18
No 215 48.2 73 52.9 142 46.1 1.00 [—]
Drug assignment
Exemestane 217 48.3 80 57.1 137 44.3 1.67 [1.12-2.51] .012
Letrozole 232 51.7 60 42.9 172 55.7 1.00 [—]
Depression: CESD
Normal 381 85 113 81.3 268 86.7 1.00 [—] .14
Possible/probable: CESD >16 67 15 26 18.7 41 13.3 1.50 [0.88-2.58]
Anxiety: HADS-A
Noncase 383 85.7 118 84.9 265 86 1.00 [—] .75
Borderline or case 64 14.3 21 15.1 43 14 1.10 [0.62-1.93]
Sleep quality: PQSI
Good: PQSI 5 224 52.1 55 41 169 57.1 1.00 [—] .002
Poor 206 47.9 79 59 127 42.9 1.91 [1.26-2.89]
Joint pain severity
None or not at all 184 41.4 50 36.2 134 43.8 1.00 [—] .14
Slight to extreme 260 58.6 88 63.8 172 56.2 1.37 [0.91-2.08]
Forgetfulness
None or not at all 239 53.6 62 44.9 177 57.5 1.00 [—] .015
Slight to extreme 207 46.4 76 55.1 131 42.5 1.66 [1.11-2.48]
Tired feeling
None or not at all 186 41.8 45 32.6 141 45.9 1.00 [—] .009
Slight to extreme 259 58.2 93 67.4 166 54.1 1.76 [1.15-2.67]
Concentration
None or not at all 342 76.7 100 71.9 242 78.8 1.00 [—] .11
Slight to extreme 104 23.3 39 28.1 65 21.2 1.45 [0.92-2.30]
Vaginal dryness
None or not at all 301 68.1 87 63 214 70.4 1.00 [—] .13
Slight to extreme 141 31.9 51 37 90 29.6 1.39 [0.91-2.13]
Abbreviations: BMI, body mass index; CESD, Center for Epidemiologic Studies-Depression; CI, confidence interval; DCIS, ductal carcinoma in situ; HADS-A,
Hospital Anxiety and Depression Scale-Anxiety; OR, odds ratio; PSQI: Pittsburgh Sleep Quality Index.
a Listed are baseline dichotomous characteristics of patients enrolled in the Exemestane and Letrozole Pharmacogenetics trial who discontinued aromatase in-
hibitor therapy because of any symptom by or at 12 months versus all others. Comparison of the cohort that discontinued versus all others was performed
using logistic regression.
bMean values are indicated in parenthesis.
c Logged values were used in logistic regression.
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associated significantly with AI discontinuation because
of symptoms. Those who discontinued therapy had a me-
dian time since surgery of 8 months (range, 1-108
months), whereas those who remained on AI therapy
beyond 12 months had a median time since surgery of 6
months (range, 0-109 months; P5 .11).
Patient-Reported Symptoms Before AI Therapy
Initiation and Treatment Discontinuation
In the ELPh trial, 67 patients (15%) reported being possi-
bly or probably depressed at the time of AI initiation
(using the CESD), and 64 patients (14.3%) reported
being borderline or definitely anxious (using the HADS-
A questionnaire) (Table 1, Fig. 2). An analysis of depres-
sive symptomatology scores as a dichotomous variable
(possibly or probably depressed vs not depressed) using
the CESD questionnaire did not demonstrate a statisti-
cally significant association between depression before AI
initiation and an increased risk of treatment discontinua-
tion within the first year (OR, 1.50; 95% CI, 0.88-2.58;
P5 .14). Similarly, no significant association was identi-
fied between pre-existing anxiety assessed using the
HADS-A questionnaire and discontinuation of AI ther-
apy (OR, 1.10; 95%CI, 0.62-1.93; P5 .75).
In the ELPh trial, 206 patients (47.9%) reported
poor sleep quality on the PSQI questionnaire before the
initiation of AI therapy (Table 1, Fig. 2). A larger percent-
age of patients who had poor sleep quality before AI initia-
tion discontinued therapy because of toxicity by 1 year
compared with those who had good sleep quality (59% vs
42.9%; OR, 1.91; 95% CI, 1.26-2.89; P5 .002). Of the
206 patients who reported poor sleep quality before AI
initiation, 139 (67.5%) reported poor sleep quality at
75% of their subsequent visits during AI therapy, and 7
who reported sleep problems at the initial assessment dis-
continued therapy before the next time point. Fifty-seven
of those 139 patients (41%) patients discontinued AI
treatment by the end of 1 year.
Other patient-reported symptoms were collected
using a general symptom questionnaire (Table 1, Fig. 2).
No statistically significant association was identified
between patient-reported presence of joint pain at base-
line and treatment discontinuation because of toxicity
(63.8% vs 56.2%, respectively; OR, 1.37; 95% CI, 0.91-
2.08; P5 .14). Patients who reported forgetfulness or
feeling tired before AI initiation were more likely to dis-
continue therapy because of toxicity compared with those
who did not report having the symptom (forgetfulness:
55.1% vs 42.5%; OR, 1.66; 95% CI, 1.11-2.48;
P5 .015; tired feeling: 67.4% vs 54.1%; OR, 1.76; 95%
CI, 1.15-2.67; P5 .009). In addition, there was no statis-
tically significant univariate association between difficulty
concentrating before starting AI therapy and treatment
discontinuation (28.1% vs 21.2%, respectively; OR,
1.45; 95% CI, 0.92-2.13; P5 .11) or vaginal dryness and
treatment discontinuation (37% vs 29.6%, respectively;
OR, 1.39; 95%CI, 0.91-2.13; P5 .13).
The following 5 symptoms were combined to assess
whether having more symptoms at baseline was associated
with treatment discontinuation: poor sleep quality (PSQI
score, >5), depression (CESD score, 16), anxiety
(HADS-A score,7), any degree of tired feeling, and any
degree of difficulty concentrating. Patients who reported a
greater number of symptoms before treatment initiation
were more likely to discontinue therapy because of toxic-
ity (Fig. 3). There was a statistically significant difference
in the treatment discontinuation rate among those who
reported the presence of 0 symptoms, 1 or 2 symptoms,
and 3 to 5 symptoms before AI initiation (P5 .007). Of
the 117 patients who did not report any of these symp-
toms at baseline, 26 (22%) discontinued AI therapy
within 1 year because of side effects. Of the 225 patients
who reported 1 or 2 symptoms before AI initiation, 69
(31%) discontinued AI therapy. In contrast, of the 107
patients who had 3 of these symptoms, 45 (42%) dis-
continued AI therapy. Compared with those patients who
reported none of the symptoms at baseline, those patients
with 1 or 2 symptoms at baseline had an increased
Figure 2. The percentage of evaluable patients who contin-
ued or discontinued aromatase inhibitor (AI) therapy within
the first year of treatment is illustrated according to baseline
symptoms that were present before AI initiation. Light bars
represent the percentage of total evaluable patients who dis-
continued AI therapy within 1 year, and dark bars represent
the percentage of total evaluable patients who continued AI
therapy beyond 1 year. Odds ratios (OR) and p values are
given for those comparisons that were statistically significant.
Conc indicates concentrating.
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likelihood of AI discontinuation during the first year
(OR, 1.55; 95% CI, 0.92-2.60), and those with 3 to 5
symptoms had an even greater increased likelihood of dis-
continuing during the first year (OR, 2.54; 95%CI, 1.42-
4.54; P5 .007). Furthermore, we observed that, on aver-
age, individuals who discontinued AI therapy within 1
year because of toxicity reported having 3 symptoms at
37% of their subsequent visits, compared with 22% of
those who did not discontinue therapy (P5 .0009).
Multivariable Analysis of Predictors of
Treatment Discontinuation Caused by Toxicity
Multivariable logistic regression was used to evaluate pre-
dictors of treatment discontinuation because of toxicity.
By including all variables in Table 1 that were related in
the univariate analysis to discontinuation, we sought a
more parsimonious model using a stepwise approach.
Thus, we evaluated a model that included age, AI medica-
tion, sleep quality, and concentration (Table 2). E1S at
baseline (P5 .14) and pain score (P5 .12) were the last
variables to be removed from the model. With all 5 varia-
bles included, the area under the curve (a measure of pre-
dictive power in logistic regression) was 0.68. In either the
full model or the reduced model (which excluded E1S
and pain score), both poor sleep quality and difficulty
concentrating remained statistically significant. In the
reduced model detailed in Table 2, those with poor sleep
quality had 1.79 times the odds of discontinuing AI medi-
cation by the end of the first year of treatment, holding
age, AI medication, and concentration severity constant
(P5 .01). Those with moderate-to-extreme difficulty
concentrating had 2.62 times the odds of discontinuing
treatment, holding all other variables constant (P5 .017).
The area under the curve of this reduced model was 0.65.
A second model was evaluated to specifically analyze
the effect of total number of symptoms at baseline (3-5
symptoms vs 0-2 symptoms) (Table 3). In this model, age
(OR, 0.97; P5 .03), AI medication (OR, 1.66; P5 .02),
and 3 symptoms (OR, 1.68; P5 .03) had statistically
significant associations with treatment discontinuation
caused by to toxicity. This model also included a pain
score (measured on a visual analog scale) in which each
1-point increase in pain increased the odds of discontinu-
ation by 1.09 (P5 .07). This model had an area under the
curve of 0.64. When baseline E1S (P5 .17) was also
included in this base model, the area under the curve
increased slightly to 0.65.
DISCUSSION
Early discontinuation of AI therapy, which is associated
with worse breast cancer outcomes, is frequently caused
TABLE 2. Multivariable Logistic Regression Analy-
sis of Predictors of Aromatase Inhibitor Treatment
Discontinuation, Including Individual Symptomsa
Variable OR (95%CI) P
Age 0.97 (0.95-1.00) .028
Drug: Exemestane vs letrozole 1.63 (1.07-2.49) .024
Sleep quality: PSQI >5 vs 5 1.79 (1.15-2.79) .010
Concentration vs none .017
Not at all or slight 0.75 (0.42-1.33)
Moderate to extreme 2.62 (1.22-5.65)
Abbreviations: CI, confidence interval; OR, odds ratio; PSQI, Pittsburgh
Sleep Quality Index.
a These are multivariable logistic regression results from a step-down analy-
sis of treatment discontinuation during the first year of aromatase inhibitor
(AI) therapy according to baseline sleep and concentration difficulties
before AI initiation and patient characteristics (n 5 428; area under the
curve 5 0.65).
Figure 3. The percentage of patients who discontinued aro-
matase inhibitor (AI) therapy is illustrated according to the
number of symptoms present before the initiation of AI ther-
apy. The total percentage of patients in each group is pro-
vided below the x-axis. OR indicates odds ratio.
TABLE 3. Multivariable Logistic Regression
Analysis of Predictors of Aromatase Inhibitor
Treatment Discontinuation, Including Symptom
Clustersa
Variable OR (95% CI) P
Age 0.97 (0.95-1.00) .025
Drug: Exemestane vs letrozole 1.66 (1.10-2.50) .016
VAS pain score 1.09 (0.99-1.20) .067
Total no. of symptoms 3 vs 2 1.68 (1.05-2.70) .031
Abbreviations: CI, confidence interval; OR, odds ratio; VAS, visual analog
scale.
a These are multivariable logistic regression results from a step-down analy-
sis of treatment discontinuation during the first year of aromatase inhibitor
(AI) therapy according to the number of symptoms present before AI initia-
tion and patient characteristics (n 5 447; area under the curve 5 0.64).
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by the development of side effects, especially musculoskel-
etal toxicity.3,5 Numerous previous studies of AI therapy
have reported an increased risk of developing musculo-
skeletal symptoms during AI treatment for factors such as
age, body mass index, pre-existing pain or arthritis, prior
chemotherapy, and prior tamoxifen.3,6-8 For the current
analysis, instead, we focused on associations between
patient-reported nonpain symptoms that were present
before the initiation of AI therapy, such as poor sleep
quality, fatigue, depression, and anxiety, and increased
rates of premature treatment discontinuation because of
toxicity. In the relatively large ELPh trial, we observed
that pre-existing poor sleep quality and difficulty concen-
trating were strongly associated with early treatment dis-
continuation because of toxicity. In addition, increased
symptom burden before AI therapy initiation was associ-
ated with both increased symptom burden during AI
treatment and increased likelihood of treatment discon-
tinuation within 1 year.
Our findings are consistent with those reported in
the MA.27 trial of exemestane versus anastrozole.26 In
that study, the hazard ratio of early treatment discontinua-
tion because of bother from side effects from previous
treatment that were present at the time of AI initiation
was 1.29 (95% CI, 1.08-1.55; P5 .006). The contribu-
tions of specific side effects were not described.
The symptom cluster of mood disorders, fatigue,
and difficulty sleeping is frequently identified in patients
across diseases, including cancer and chronic pain syn-
dromes.27 Many of the published reports evaluating
symptom clusters in breast cancer patients have focused
on patients undergoing therapy with short-term treatment
modalities, including chemotherapy and=or radiation
therapy. For example, in 1 study, patients who reported a
greater number of symptoms before the start of chemo-
therapy were more likely to report worse symptoms dur-
ing the treatment.27 Other studies have identified specific
patterns of change in symptoms over time during chemo-
therapy and radiation. These patterns ultimately impact
functional status and quality of life, and they may influ-
ence patient management.17,28 In contrast, few published
reports have focused on patterns of specific symptoms
that occur during long-term adjuvant endocrine therapy.
Analogous to what has been observed previously with
chemotherapy, in the ELPh trial, we identified an associa-
tion between a greater number of symptoms before treat-
ment and decreased persistence with AI therapy because
of toxicity. The symptoms of poor sleep and difficulty
concentrating stood out as clinically important contribu-
tors to this symptom cluster.
Knowledge of these associations is clinically relevant,
because these symptoms are not frequently recognized as
problematic and are not typically carefully assessed or
aggressively managed by oncologists. Indeed, because diffi-
culty sleeping and complaints of fatigue are common
among patients with breast cancer29 and often are believed
to be self-limited side effects of prior therapies, including
chemotherapy and radiation therapy, oncologists may not
appreciate that the presence of these symptoms could com-
promise future treatments. These results raise the possibility
that asking patients about these symptoms and addressing
them at the time of AI initiation, or even prophylactically,
could identify patients at risk and allow the implementa-
tion of measures to improve adherence=persistence with
subsequent adjuvant endocrine therapy.
Although the management of these symptoms is
essential for improving quality of life, the current data
suggest that it may also have an impact on breast cancer
outcomes if improvement in symptoms leads to increased
adherence to and persistence with therapy. There is a pau-
city of effective treatment options for poor sleep, cognitive
problems, and fatigue among cancer survivors. Numerous
clinical trials have been conducted to test various pharma-
cologic therapies for fatigue, although few studies of phar-
macologic treatments have been conducted specifically for
sleep disturbance in cancer patients.18 Meta-analyses have
demonstrated a statistically significant benefit from meth-
ylphenidate compared with placebo for cancer-related fa-
tigue, although the clinical benefit is modest.30 There are
also considerable data supporting the use of cognitive be-
havioral therapy for treatment of both insomnia and fa-
tigue in cancer patients.30-32 The use of cognitive
behavioral therapy is recommended in the National Com-
prehensive Cancer Network guidelines for the manage-
ment of cancer-related fatigue,33 although it is unknown
how often these behavioral techniques are actually used in
clinical practice. Improvements in fatigue have also been
noted in patients with cancer who received other non-
pharmacologic interventions, including physical activ-
ity.30 Although several treatment options are listed in the
currently available national guidelines, no individual mo-
dality is preferred.33
Our study has multiple strengths. The findings were
derived from a large, prospective clinical trial in which
reasons for discontinuation were prospectively recorded.
Validated questionnaires were used to assess patient-
reported sleep, pain, and mood disorders, although
fatigue and cognitive function data elements had to be
obtained from a more general symptom questionnaire.
The study medication was provided to the patients by the
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study, so cost of the medication was not a factor in persist-
ence with therapy.
In this analysis, we identified a numerically greater
but not statistically significant increased risk of treatment
discontinuation within 1 year among patients who
received a taxane-based chemotherapy regimen, which we
and others have previously reported. One important dif-
ference between the prior analysis of the ELPh trial and
the current report is the focus on discontinuation specifi-
cally within the first year of AI therapy. This 1-year limita-
tion was intended to restrict analyses to the symptoms
likely caused by the AI medication and less likely caused
by changes that can occur over time with the natural aging
process, such as worsening osteoarthritis. Our findings
suggest that pre-existing symptoms are more strongly
associated with AI discontinuation because of toxicity
than clinical factors, such as prior chemotherapy. How-
ever, it remains possible that prior treatments like chemo-
therapy contributed to the symptoms reported by patients
at the time of their baseline study visit.
Our findings demonstrate the importance of symp-
tom clusters that include poor sleep and difficulty concen-
trating in patients with breast cancer and the potential
detrimental effects of these symptoms not just on quality
of life but also on AI treatment adherence and breast can-
cer outcomes. Therapies to improve the constellation of
symptoms rather than those that target individual symp-
toms should be considered to allow optimal patient care.
Clinical trials are warranted to evaluate the impact of the
management of symptom clusters on adherence to poten-
tially life-saving adjuvant endocrine therapies.
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